An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems

作者：Wachter Rolf^*; Halbach Marcel; Bakris George L; Bisognano John D; Haller Hermann; Beige Joachim; Kroon Abraham A; Nadim Mitra K; Lovett Eric G; Schafer Jill E; de Leeuw Peter W

来源：Journal of the American Society of Hypertension, 2017, 11(2): 81-91.

DOI：10.1016/j.jash.2016.12.003

• Autonomic nervous system
• baroreflex
• resistant hypertension
• sham control

Barorefiex activation therapy (BAT) is a device-based therapy for patients with treatment-resistant hypertension. In a randomized, controlled trial, the first-generation system significantly reduced blood pressure (BP) versus sham. Although an open label validation study of the second-generation system demonstrated similar BP reductions, controlled data are not presently available. Therefore, this investigation compares results of first- and second-generation BAT systems. Two cohorts of first-generation BAT system patients were generated with propensity matching to compare against the validation group of 30 second-generation subjects. The first cohort was drawn from the first-generation randomized trial sham group and the second cohort from the active therapy group. Safety and efficacy were compared for the second-generation group relative to the first generation. At 6 months, second-generation BAT outperformed first-generation sham systolic BP reduction by 20 +/- 28 mm Hg (mean +/- standard deviation, P = .008), while BP reduction in first- and second-generation active groups was similar. At 12 months, efficacy was comparable between all three groups after the sham group had received 6 months of therapy; 47% of second-generation patients achieved goal systolic BP of 140 mm Hg or less after 12 months, comparable to 50% of patients at goal in the first-generation group (P > .999). Implant procedure time, system/procedural safety, and pulse generator longevity improved with the second-generation system. Propensity-matched cohort analysis of the first- and second-generation BAT systems suggests similar therapeutic benefit and superior BP reduction of the second-generation system relative to sham control. Implantation procedure duration and perioperative safety were improved with the second-generation device. These findings should be validated in a prospective randomized trial.

• 出版日期2017-2